Moderna, Inc. 8-K Filing
Ticker: MRNA · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Moderna, Inc. (ticker: MRNA) to the SEC on Nov 20, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market).
How long is this filing?
Moderna, Inc.'s 8-K filing is 2 pages with approximately 508 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-11-20 07:12:22
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
Filing Documents
- mrna-20251120.htm (8-K) — 29KB
- exhibit9912025analystday.htm (EX-99) — 32KB
- 0001628280-25-053318.txt ( ) — 182KB
- mrna-20251120.xsd (EX-101.SCH) — 2KB
- mrna-20251120_lab.xml (EX-101.LAB) — 21KB
- mrna-20251120_pre.xml (EX-101.PRE) — 12KB
- mrna-20251120_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 20, 2025, Moderna, Inc. (the "Company") issued a press release highlighting pipeline progress and business strategy updates in connection with the Company's Analyst Day on the same date. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated November 20 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2025 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer